Overview

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

Status:
Recruiting

Trial end date:
2022-04-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the treatment of solid tumors with various immunotherapy combinations. The treatment will be determined based upon a broad biomarker assessment.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Glucocorticoids
Ipilimumab
Linrodostat
Nivolumab